



GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights

July 29, 2025

- Reported second quarter 2025 revenues of \$102.7 million with 69% year-over-year growth of exome and genome test revenue
- Expanded adjusted gross margin to 71% and generated adjusted net income¹ of \$15.0 million for the second quarter 2025
- Raised guidance to deliver between \$400 and \$415 million in revenue with between 48% to 52% full year growth in exome and genome revenue
- Announced American Academy of Pediatrics (AAP) now recommends pediatricians use exome and genome testing as first-line for children with global developmental delay or intellectual disability
- Hosting conference call today at 8:30 a.m. ET

GAITHERSBURG, Md.--(BUSINESS WIRE)--Jul. 29, 2025-- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2025.

“Crossing the \$100 million revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx, putting us on a path for more growth at scale and enabling us to reach more patients while reducing unnecessary spend across the global healthcare system,” said Katherine Stueland, CEO of GeneDx. “Our strong second quarter performance was driven by our core business, underscoring its strength and resilience. These results, coupled with the ever-expanding opportunities ahead, including general pediatrics, demonstrate that we’re just beginning to deliver on the promise of how our technology can fundamentally change the way genomics can inform healthcare, shifting from reactive to proactive care.”

Second Quarter 2025 Financial Results (Unaudited)^{1,2}

Revenues

- Revenues grew to \$102.7 million, an increase of 49% year-over-year.
- Exome and genome test revenue grew to \$85.9 million, an increase of 69% year-over-year.

Exome and genome volume

- Exome and genome test results volume grew to 23,102, an increase of 28% year-over-year.
- Exome and genome represented 41% of all tests, up from 31% in the second quarter of 2024.

Gross margin

- Adjusted gross margin expanded to 71%, up from 62% in the second quarter of 2024.
 - Total GAAP gross margin was 69%.

Operating expenses

- Adjusted total operating expenses were \$57.8 million, representing 56% of revenue in the second quarter of 2025, compared to 65% of revenue in the second quarter of 2024.
 - Total GAAP operating expenses were \$61.9 million.

Net Income

- Adjusted net income was \$15.0 million compared to an adjusted net loss of \$2.0 million in the second quarter of 2024.
 - GAAP net income was \$10.8 million.

Cash position

- Cash, cash equivalents, marketable securities and restricted cash was \$135.5 million as of June 30, 2025.
- Cash flow for the second quarter 2025 primarily included:
 - \$33.2 million used to acquire Fabric Genomics, net of cash acquired, partially offset by;
 - \$10.4 million in cash generated from operations.

1. Revenue and adjusted gross margin growth rates exclude revenue and costs of sales from the exited Legacy Sema4 diagnostic testing business.

2. Adjusted gross margin, adjusted total operating expenses and adjusted net income/(loss) are non-GAAP financial measures. See appendix for a reconciliation of GAAP to Non-GAAP figures presented.

GeneDx Full Year 2025 Guidance

GeneDx has raised certain elements of its full year 2025 guidance and expects to deliver:

Metric	Previous Guidance	Updated Guidance
Revenue	\$360 to \$375 million	\$400 to \$415 million
Growth in exome and genome revenue	30%	48% to 52%
Growth in exome and genome volume	30%	30%
Adjusted gross margin	66% to 68%	68% to 71%
Adjusted net income	Positive each quarter and for full year	Positive each quarter and for full year

Second Quarter 2025 and Recent Business Highlights

Strategic Expansion and Market Access

- Announced that the [American Academy of Pediatrics now recommends](#) exome and genome sequencing as first-tier tests for children with global developmental delay or intellectual disability, positioning pediatricians to offer exome and genome testing to their patients.
- Expanded commercial focus to include calling on providers treating children with [inborn errors of immunity \(IEI\)](#), a group of nearly 500 genetic disorders that impair immune function.
- Accelerated adoption of exome and genome sequencing coverage by state Medicaid programs, bringing the total states covering exome or genome sequencing in the pediatric outpatient setting to 35 with the recent addition of Colorado and Maine, and the total states covering rapid genome sequencing in the neonatal intensive care unit (NICU) to 17 with the recent addition of Virginia, Ohio, and Oklahoma.

Innovation & Clinical Leadership

- Acquired [Fabric Genomics](#), enabling a hybrid centralized and decentralized model for delivering genomic insights globally.
- Published SeqFirst study in the [Journal of Pediatrics](#), showing rapid genomic testing reduced time to diagnosis from about 10 months to 13 days.
- Published data in the [American Journal of Medical Genetics](#) underscoring GeneDx's leadership in leveraging artificial intelligence (AI) to increase diagnostic yield and improve healthcare for patients with genetic conditions.

Webcast and Conference Call Details

GeneDx will host a conference call today, July 29, 2025, at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at <https://ir.genedx.com/>.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our future performance, future operations, plans, objectives of management, and our market opportunity, including our expected full year 2025 reported revenue, volume, adjusted gross margin and adjusted net income. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to utilize our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" sections of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC") on February 20, 2025, and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, filed with the SEC on April 30, 2025 and July 29, 2025, respectively, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or

revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

About GeneDx

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit [genedx.com](https://www.genedx.com) and connect with us on [LinkedIn](#), [Facebook](#), and [Instagram](#).

Volume & Revenue ¹

	2Q25	1Q25	4Q24	3Q24	2Q24
Volumes					
Whole exome, whole genome	23,102	20,562	20,676	19,262	18,017
Hereditary cancer	2,677	2,725	3,486	4,672	5,482
Other panels	29,894	28,228	30,115	35,095	34,204
Total	55,673	51,515	54,277	59,029	57,703
Revenue (\$ millions)					
Whole exome, whole genome	\$ 85.9	\$ 71.4	\$ 78.8	\$ 60.0	\$ 50.7
Hereditary cancer	1.8	2.2	2.8	3.3	3.8
Other panels	12.1	12.1	12.3	13.8	13.3
Data information	2.0	1.4	1.4	(0.5)	1.1
Fabric Genomics	0.9	—	—	—	—
Total	\$ 102.7	\$ 87.1	\$ 95.3	\$ 76.6	\$ 68.9

1. Excludes volume and revenue from the exited Legacy Sema4 diagnostic testing business.

Unaudited Select Financial Information (in thousands)

	Three months ended June 30, 2025			Three months ended June 30, 2024		
	GeneDx	Other ¹	Total	GeneDx	Other ¹	Total
Revenue	\$ 101,784	\$ 908	\$ 102,692	\$ 68,924	\$ 1,590	\$ 70,514
Adjusted cost of services	29,964	244	30,208	26,523	145	26,668
Adjusted gross profit (loss)	\$ 71,820	\$ 664	\$ 72,484	\$ 42,401	\$ 1,445	\$ 43,846
Adjusted gross margin %	70.6%	73.1%	70.6%	61.5%	90.9%	62.2%

1. Other includes revenue and cost of services from the Legacy Sema4 diagnostic testing business for both periods presented. For the three months ended June 30, 2025, Other includes revenue and cost of services from Fabric Genomics.

	Three months ended June 30, 2025						
	Reported	Depreciation and amortization	Stock-based compensation expense	Restructuring costs	Change in FV of financial liabilities	Other	Adjusted
Diagnostic test revenue	\$ 99,823	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 99,823
Other revenue	2,869	—	—	—	—	—	2,869
Total revenue	102,692	—	—	—	—	—	102,692
Cost of services	31,790	(1,389)	(193)	—	—	—	30,208
Gross profit (loss)	70,902	1,389	193	—	—	—	72,484
Gross margin	69.0%						70.6%
Research and development	15,079	(209)	(1,422)	—	—	—	13,448
Selling and marketing	19,448	(1,298)	(1,268)	—	—	—	16,882

General and administrative	27,415	(3,295)	(4,930)	(73)	—	8,342	27,459
Loss from operations	8,960	6,191	7,813	73	—	(8,342)	14,695
Interest income (expense), net	(817)	—	—	—	—	817	—
Other income (expense), net	2,420	—	—	—	(2,181)	49	288
Income tax benefit	246	—	—	—	—	(246)	—
Net income	<u>\$ 10,809</u>	<u>\$ 6,191</u>	<u>\$ 7,813</u>	<u>\$ 73</u>	<u>\$ (2,181)</u>	<u>\$ (7,722)</u>	<u>\$ 14,983</u>

Basic earnings per share* \$ 0.38 \$ 0.52

Diluted earnings per share* \$ 0.36 \$ 0.50

* Basic and diluted earnings per share are calculated based on 28,579,704 and 29,753,933 weighted average shares outstanding for the three months ended June 30, 2025, respectively.

Three months ended June 30, 2024

	Reported	Depreciation and amortization	Stock-based compensation expense	Restructuring costs	Change in FV of financial liabilities	Other ¹	Adjusted
Diagnostic test revenue	\$ 69,439	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 69,439
Other revenue	1,075	—	—	—	—	—	1,075
Total revenue	70,514	—	—	—	—	—	70,514
Cost of services	27,562	(808)	(86)	—	—	—	26,668
Gross profit (loss)	42,952	808	86	—	—	—	43,846
Gross margin	60.9%						62.2%
Research and development	10,902	(211)	(347)	(35)	—	—	10,309
Selling and marketing	16,585	(1,225)	(368)	(63)	—	—	14,929
General and administrative	26,044	(2,974)	(2,307)	(150)	—	—	20,613
Loss from operations	(10,579)	5,218	3,108	248	—	—	(2,005)
Interest income (expense), net	(894)	—	—	—	—	894	—
Other income (expense), net	(17,890)	—	—	—	4,409	13,450	(31)
Income tax benefit	190	—	—	—	—	(190)	—
Net loss	<u>\$ (29,173)</u>	<u>\$ 5,218</u>	<u>\$ 3,108</u>	<u>\$ 248</u>	<u>\$ 4,409</u>	<u>\$ 14,154</u>	<u>\$ (2,036)</u>

Basic loss per share* \$ (1.10) \$ (0.08)

Diluted loss per share* \$ (1.10) \$ (0.08)

* Basic and diluted loss per share are calculated based on 26,617,955 diluted weighted average shares outstanding for the three months ended June 30, 2024.

1. Other represents interest expense, net, and income tax (expense) benefit for all periods presented. Other for the three months ended June 30, 2025 includes transaction costs related to the acquisition of Fabric Genomics. Other for the three months ended June 30, 2024 includes legal costs related to a legal settlement.

GeneDx Holdings Corp.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)

June 30, 2025 (Unaudited)	December 31, 2024
--	------------------------------------

Assets:

Current assets:

Cash and cash equivalents	\$ 74,120	\$ 85,212
Marketable securities	60,438	55,973
Accounts receivable	48,028	37,629
Inventory, net	11,932	10,650
Prepaid expenses and other current assets	10,319	8,504
Total current assets	<u>204,837</u>	<u>197,968</u>
Operating lease right-of-use assets	24,978	25,613
Property and equipment, net	40,120	32,893
Goodwill	12,926	—
Intangible assets, net	176,689	158,600
Other assets ¹	4,313	4,306
Total assets	<u>\$ 463,863</u>	<u>\$ 419,380</u>

Liabilities and Stockholders' Equity:

Current liabilities:

Accounts payable and accrued expenses	\$ 49,239	\$ 30,983
Short-term lease liabilities	3,083	3,336
Other current liabilities	19,084	20,498
Total current liabilities	<u>71,406</u>	<u>54,817</u>
Long-term debt, net of current portion	51,683	51,913
Long-term lease liabilities	59,619	60,919
Other liabilities	3,275	5,519
Deferred taxes	747	965
Total liabilities	<u>186,730</u>	<u>174,133</u>

Stockholders' Equity:

Preferred stock	—	—
Class A common stock	2	2
Additional paid-in capital	1,624,513	1,596,889
Accumulated deficit	(1,348,194)	(1,352,474)
Accumulated other comprehensive income	812	830
Total stockholders' equity	<u>277,133</u>	<u>245,247</u>
Total liabilities and stockholders' equity	<u>\$ 463,863</u>	<u>\$ 419,380</u>

1. Other assets includes \$990 thousand of restricted cash as of both June 30, 2025 and December 31, 2024.

GeneDx Holdings Corp.
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except share and per share amounts)

	Three months ended June 30,		Six months ended June 30,	
	2025	2024	2025	2024
Revenue				
Diagnostic test revenue	\$ 99,823	\$ 69,439	\$ 185,582	\$ 130,543
Other revenue	2,869	1,075	4,225	2,393
Total revenue	<u>102,692</u>	<u>70,514</u>	<u>189,807</u>	<u>132,936</u>
Cost of services	<u>31,790</u>	<u>27,562</u>	<u>60,429</u>	<u>52,573</u>
Gross profit	<u>70,902</u>	<u>42,952</u>	<u>129,378</u>	<u>80,363</u>
Research and development	15,079	10,902	27,656	22,469
Selling and marketing	19,448	16,585	37,764	32,670
General and administrative	27,415	26,044	59,549	49,463
Income (loss) from operations	<u>8,960</u>	<u>(10,579)</u>	<u>4,409</u>	<u>(24,239)</u>
Non-operating income (expenses), net				

Change in fair value of warrants and contingent liabilities	2,181	(4,409)	1,081	(10,510)
Interest expense, net	(817)	(894)	(1,457)	(1,491)
Other income (expense), net	239	(13,481)	448	(13,444)
Total non-operating income (expense), net	1,603	(18,784)	72	(25,445)
Income (loss) before income taxes	10,563	(29,363)	\$ 4,481	\$ (49,684)
Income tax benefit (expense)	246	190	(201)	272
Net income (loss)	\$ 10,809	\$ (29,173)	\$ 4,280	\$ (49,412)

Weighted average shares outstanding of Class A common stock - Basic	28,579,704	26,617,955	28,365,018	26,340,063
Earnings (loss) per share, Class A common stock- Basic	\$ 0.38	\$ (1.10)	\$ 0.15	\$ (1.88)
Weighted average shares outstanding of Class A common stock - Diluted	29,753,933	26,617,955	29,642,555	26,340,063
Earnings (loss) per share, Class A common stock- Diluted	\$ 0.36	\$ (1.10)	\$ 0.14	\$ (1.88)

GeneDx Holdings Corp.
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)

	Six months ended June 30,	
	2025	2024
Operating activities		
Net income (loss)	\$ 4,280	\$ (49,412)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Depreciation and amortization expense	11,869	10,466
Stock-based compensation expense	11,796	2,657
Change in fair value of warrants and contingent liabilities	(1,081)	10,510
Deferred tax expense (benefit)	202	(272)
Provision for excess and obsolete inventory	123	109
Legal reserves	—	13,450
Change in third party payor reserves	5,014	1,066
Other	1,387	1,738
Change in operating assets and liabilities:		
Accounts receivable	(9,889)	6,622
Inventory	(1,404)	(1,654)
Accounts payable and accrued expenses	7,199	(10,871)
Other assets and liabilities	(8,894)	(5,327)
Net cash provided by (used in) operating activities	20,602	(20,918)
Investing activities		
Acquisition of business, net of cash acquired	(33,195)	—
Purchases of property and equipment	(8,498)	(1,795)
Purchases of marketable securities	(30,770)	(29,381)
Proceeds from sales of marketable securities	—	598
Proceeds from maturities of marketable securities	26,705	8,720
Net cash used in investing activities	(45,758)	(21,858)
Financing activities		
Proceeds from offerings, net of issuance costs	13,766	—
Proceeds from issuance of common stock pursuant to employee stock purchase plan	1,262	—
Exercise of stock options	800	161
Long-term debt principal payments	(602)	—
Finance lease principal payments	(1,162)	(990)
Net cash provided by (used in) financing activities	14,064	(829)
Net decrease in cash, cash equivalents and restricted cash	(11,092)	(43,605)
Cash, cash equivalents and restricted cash, at beginning of period	86,202	100,668
Cash, cash equivalents and restricted cash, at end of period ⁽¹⁾	\$ 75,110	\$ 57,063

Supplemental disclosures of cash flow information

Cash paid for interest	\$ 3,210	\$ 4,033
Cash paid for taxes	\$ 920	\$ 557
Stock consideration paid pursuant to exercise of Perceptive warrant	\$ —	\$ 12,586
Purchases of property and equipment in accounts payable and accrued expenses	\$ 5,752	\$ 501
Assets acquired under capital lease obligations	\$ —	\$ 689

1. Cash, cash equivalents and restricted cash at June 30, 2025 excludes marketable securities of \$60.4 million.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250729547446/en/): <https://www.businesswire.com/news/home/20250729547446/en/>

Investor Relations Contact:

Investors@GeneDx.com

Media Contact:

Press@GeneDx.com

Source: GeneDx